How I treat transfusional iron overload

A. Victor Hoffbrand, Ali Taher, Maria Domenica Cappellini

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Patients with β-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions accumulate iron that damages the liver, endocrine system, and most importantly the heart. The prognosis in TM has improved remarkably over the past 10 years. This improvement has resulted from the development of magnetic resonance imaging (MRI) techniques, especially T2*, to accurately measure cardiac and liver iron, and from the availability of 3 iron-chelating drugs. In this article we describe the use of MRI to determine which adult and pediatric patients need to begin iron chelation therapy and to monitor their progress.We summarize the properties of each of the 3 drugs, deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including their efficacy, patient acceptability, and side effects. We describe when to initiate or intensify therapy, switch to another drug, or use combined therapy. We also discuss the management of refractory anemias other than TM that may require multiple blood transfusions, including sickle cell anemia and myelodysplasia. The development of a potential fourth chelator FBS 0701 and the combined use of oral chelators may further improve the quality of life and survival in patients with TM and other transfusion-dependent patients.

Original languageEnglish
Pages (from-to)3657-3669
Number of pages13
JournalBlood
Volume120
Issue number18
DOIs
Publication statusPublished - Nov 1 2012

Fingerprint

Iron Overload
beta-Thalassemia
Iron
Refractory Anemia
Magnetic resonance
Chelating Agents
Chelation
Liver
Refractory materials
Blood
Blood Transfusion
Pharmaceutical Preparations
Imaging techniques
Pediatrics
Deferoxamine
Magnetic Resonance Imaging
Chelation Therapy
Endocrine System
Sickle Cell Anemia
Switches

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

How I treat transfusional iron overload. / Hoffbrand, A. Victor; Taher, Ali; Cappellini, Maria Domenica.

In: Blood, Vol. 120, No. 18, 01.11.2012, p. 3657-3669.

Research output: Contribution to journalArticle

Hoffbrand, A. Victor ; Taher, Ali ; Cappellini, Maria Domenica. / How I treat transfusional iron overload. In: Blood. 2012 ; Vol. 120, No. 18. pp. 3657-3669.
@article{72c5b63d869447068de72fa9ac58301f,
title = "How I treat transfusional iron overload",
abstract = "Patients with β-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions accumulate iron that damages the liver, endocrine system, and most importantly the heart. The prognosis in TM has improved remarkably over the past 10 years. This improvement has resulted from the development of magnetic resonance imaging (MRI) techniques, especially T2*, to accurately measure cardiac and liver iron, and from the availability of 3 iron-chelating drugs. In this article we describe the use of MRI to determine which adult and pediatric patients need to begin iron chelation therapy and to monitor their progress.We summarize the properties of each of the 3 drugs, deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including their efficacy, patient acceptability, and side effects. We describe when to initiate or intensify therapy, switch to another drug, or use combined therapy. We also discuss the management of refractory anemias other than TM that may require multiple blood transfusions, including sickle cell anemia and myelodysplasia. The development of a potential fourth chelator FBS 0701 and the combined use of oral chelators may further improve the quality of life and survival in patients with TM and other transfusion-dependent patients.",
author = "Hoffbrand, {A. Victor} and Ali Taher and Cappellini, {Maria Domenica}",
year = "2012",
month = "11",
day = "1",
doi = "10.1182/blood-2012-05-370098",
language = "English",
volume = "120",
pages = "3657--3669",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "18",

}

TY - JOUR

T1 - How I treat transfusional iron overload

AU - Hoffbrand, A. Victor

AU - Taher, Ali

AU - Cappellini, Maria Domenica

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Patients with β-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions accumulate iron that damages the liver, endocrine system, and most importantly the heart. The prognosis in TM has improved remarkably over the past 10 years. This improvement has resulted from the development of magnetic resonance imaging (MRI) techniques, especially T2*, to accurately measure cardiac and liver iron, and from the availability of 3 iron-chelating drugs. In this article we describe the use of MRI to determine which adult and pediatric patients need to begin iron chelation therapy and to monitor their progress.We summarize the properties of each of the 3 drugs, deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including their efficacy, patient acceptability, and side effects. We describe when to initiate or intensify therapy, switch to another drug, or use combined therapy. We also discuss the management of refractory anemias other than TM that may require multiple blood transfusions, including sickle cell anemia and myelodysplasia. The development of a potential fourth chelator FBS 0701 and the combined use of oral chelators may further improve the quality of life and survival in patients with TM and other transfusion-dependent patients.

AB - Patients with β-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions accumulate iron that damages the liver, endocrine system, and most importantly the heart. The prognosis in TM has improved remarkably over the past 10 years. This improvement has resulted from the development of magnetic resonance imaging (MRI) techniques, especially T2*, to accurately measure cardiac and liver iron, and from the availability of 3 iron-chelating drugs. In this article we describe the use of MRI to determine which adult and pediatric patients need to begin iron chelation therapy and to monitor their progress.We summarize the properties of each of the 3 drugs, deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including their efficacy, patient acceptability, and side effects. We describe when to initiate or intensify therapy, switch to another drug, or use combined therapy. We also discuss the management of refractory anemias other than TM that may require multiple blood transfusions, including sickle cell anemia and myelodysplasia. The development of a potential fourth chelator FBS 0701 and the combined use of oral chelators may further improve the quality of life and survival in patients with TM and other transfusion-dependent patients.

UR - http://www.scopus.com/inward/record.url?scp=84868539376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868539376&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-05-370098

DO - 10.1182/blood-2012-05-370098

M3 - Article

VL - 120

SP - 3657

EP - 3669

JO - Blood

JF - Blood

SN - 0006-4971

IS - 18

ER -